^
Association details:
| Biomarker: | ESRP1-RAF1 fusion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Excerpt:
We also observed a dramatic increase in cell invasion in RWPE cells expressing either SLC45A3-BRAF or ESRP1-RAF1, which was sensitive to sorafenib or the MEK inhibitor U0126.
DOI:
10.1038/nm.2166
